Michael R. Diehl

This paper develops a cell-based therapy that enables sustained, dose-tunable delivery of monoclonal antibodies through a single administration, demonstrating long-term efficacy and safety in preclinical models.

The paper uses CRISPRa to show that transcriptional memory can be induced in MSCs through locus-specific activation, linked to H3K27me3 loss and increased transcription factor reacquisition.

This study evaluates the pharmacokinetics of a human mAb in different mouse strains to identify suitable models for preclinical testing.

This paper introduces a genetic priming method using IRF1 to sustainably enhance MSC potency and suppress immunogenicity compared to biochemical priming.